Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|June 1, 1998
Supplements and Featured Publications
- Treatment of Heart Failure: A Managed Care Perspective
- Volume 4
- Issue 6 Suppl
Participating Faculty
Advertisement
Articles in this issue
over 28 years ago
Introduction: Treatment of Heart Failure: A Managed Care Perspectiveover 28 years ago
Epidemiology, Prevalence, Treatments, and Clinical Trialsover 28 years ago
Clinical Practice Guidelines for Heart Failureover 28 years ago
Cost of Heart Failure to the Healthcare Systemover 28 years ago
Heart Failure and Disease Managementover 28 years ago
Selected Abstractsover 28 years ago
CME Quizover 28 years ago
BibliographyAdvertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5